Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.

Slides:



Advertisements
Similar presentations
Department of Neurology, Mayo Clinic Arizona
Advertisements

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.
The Alzheimer’s Disease Genetics Initiative: Multiplex Family Study October 17 th Meeting—San Francisco, CA Columbia University, NCRAD, and the National.
Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager Dementias and Neurodegenerative.
Population-based Neuropathology: classification of disease biomarker discovery tool Thomas J. Montine, MD, PhD Alvord Professor and Chair Department of.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
ADNI 3 Clinical Core Plans
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong,
BERG SYMPOSIUM WASHINGTON UNIVERSITY SEPT 2003 MICHAEL W WEINER MD.
Dementia with Lewy Bodies
Mild Cognitive Impairment
Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.
Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Presented by: Beau Ances,
Institute on Aging University of Pennsylvania Alternative Funding Strategies and the Power of Fundraising John Q. Trojanowski, M.D., Ph.D. Institute on.
Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.
FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.
CLINICAL & TRANSLATIONAL SCIENCE AWARDS CLINICAL & TRANSLATIONAL SCIENCE AWARDS Transforming Biomedical Research To Improve the Health of Our Nation’s.
Department of Neurology
Desirable Surveillance Network National Prion Disease Pathology Surveillance Center Locations Regularly Performing.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
Julie A. Schneider MD MS Professor, Departments of Pathology and Neurological Sciences Associate Director, Neuropathology Core Leader, Rush Alzheimer’s.
G. Scott Gazelle, MD, MPH, PhD Director, Partners Radiology Partners Radiology Research Retreat February 26, 2010.
Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.
CL Ropp 1, SL Tyas 1, KP Riley 2, KS SantaCruz 3 1 University of Waterloo, 2 University of Kentucky, 3 University of Minnesota March 29, 2011 The Impact.
A Tour of America's Best Hospitals It's no secret that all hospitals are not equal  The special quality shared by the 152 that made it into.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.
Center-Specific Neuropathology Procedures Survey Erin M. Pfeiffer 10/12/2002 NACC National Alzheimer’s Coordinating Center.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
conflicts of interest to report.
Effects of traumatic brain injury (TBI) & post traumatic stress disorder (PTSD) on Alzheimer’s disease (AD) in Veterans using ADNI (DOD ADNI) Michael.
Recent advances in Trace Element Research in Health and Disease Dubrovnik, Oct 2015 Mirjana Babić Leko, mag.biol.mol Department of Neuroscience Croatian.
High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.
Clifford R Jack Jr MD Professor of Radiology
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.
Mariano Musacchio 1 François Sellal 2 Frédéric Blanc 2 Jean-Marc Michel 2 Stephan Kremer 3 Jean-Louis Dietemann 3 1 Department of Neuroradiology - CHG.
Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Absence of β-Amyloid Deposits After Immunization in.
Dementia with Lewy Bodies
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE   Mirjana Babić Leko1, Matea Nikolac Perković2,
Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;
Dementia: from molecules to minds
Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer#cod#x02019;s Disease and Related Tauopathies Diana L Castillo-Carranza 1, 2 ;Ashley N.
The Carroll A. Campbell, Jr. Neuropathology Laboratory (Brain Bank)
Fig. 11. Algorithm for differential diagnosis of cognitive impaired subjects by employing structural imaging. AD = Alzheimer's disease, BG = basal ganglia,
Table 2. Data Sharing for (Reporting Period)
Volume 2, Issue 1, Pages (January 2016)
65 year-old female with Alzheimer’s disease
PPMI Pathology Core Tatiana Foroud & Tom Montine.
Early Dementia Distinguishing AD From MCI
John F. Crary, MD-PhD Associate Professor
ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue
AAIC 2018 Biomarker Rates of Change in Autosomal Dominant Versus “Sporadic” Alzheimer Disease John C. Morris, MD On behalf of MW Weiner, L Beckett, T.
Does Multilingualism Protect Against Alzheimer’s Disease
New CHEST Editorial Board Members
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Argentina Arg-ADNI Ezequiel Surace, PhD.
NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease Clifford R Jack Jr MD Prof. of Radiology and Alexander Family Professor.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
From Innovation to Commercialization Access to Data
Background of PI Name: Wen-Yih Isaac Tseng, MD, PhD
Presentation transcript:

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS

Table 1. ADNI Autopsy Rates ( to ) Note: The ADNI-NPC was established on 9/1/2007. ADNI Funding Period ADNI-NPCDeathsAutopsies Annual Autopsy Rate (%) to N to YES to YES to YES to YES to YES to YES to YES10990 Total ( ) Total since NPC established

Table 2. Brains Donated by ADNI Sites Site IDSite NameAutopsies (#) 11 Washington University School of Medicine, St. Louis7 33 University of Kansas5 23 University of Kentucky4 31 University of Texas, Southwestern MC3 24 University of Pittsburgh2 99 Banner Sun Health Research Institute2 116 University of California, Davis2 27 University of Rochester Medical College2 32 Emory University1 41 Yale University School of Medicine1 73 University of California, San Francisco1 114 Case Western Reserve University1 123 Dent Neurologic Institute1 131 Albany Medical College1 141 Rhode Island Hospital1 941 Butler Hospital Memory and Aging Program1 37 Indiana University1 29 University of California, Irvine1

Clinical and Demographic Data on Autopsied Cases l N = 37 l Mean Age: 81 years l Male: 81% l ε4-positive: 57% (2 cases pending) l Clinically Diagnosed –AD Dementia: 76% –MCI-amnestic:11% –Pending: 13%

Table 3. Clinical and Neuropathologic Diagnoses at Expiration Note: N, number of ADNI cases. AD, Alzheimer’s disease; AGD, argyrophilic grain disease; DAT, dementia of the Alzheimer type; DLB, dementia with Lewy bodies; ALB, Amygdala Lewy bodies; HS, Hippocampal sclerosis; MCI, mild cognitive impairment; TDP, TDP-43 proteinopathy in the medial temporal lobe. * One case had additional AGD. Small vessel disease (arteriolosclerosis and cerebral amyloid angiopathy) was a feature of all cases bit only one case had infarcts. Clinical diagnosis Neuropathologic diagnosis [N (%)] TOTAL (%)^ AD +DLB AD +DLB +TDP AD + DLB +TDP +AGD AD +ALB +TDP AD + AGD AD + HS + AGD AD +TDP +Infarcts AGD Pending# DAT98* (68) DAT+DLB1113 (8) MCI- Amnestic 21**14 (11) Pending^^55 (13) TOTAL (%) 11 (28) 8 (22) 2 (5) 1 (3) 1 (3) 1 (3) 1 (3) 1 (3) 1 (3) 10 (27) 37 (100)

Clinical and Multimodal Biomarker Correlates of Neuropathology in 22 ADNI Cases Jon B. Toledo a *, Nigel J. Cairns b *, Xiao Da c, Kewei Chen d, Deborah Carter b, Napatkamon Ayutyanont d, Erin Householder b, Auttawut Roontiva d, Robert J Bauer d, Leslie M. Shaw a, Christos Davatzikos c, Michael W. Weiner e, Eric Reiman d, John Morris b ** and John Q. Trojanowski a **, and the Alzheimer’s Disease Neuroimaging Initiative*** a Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, b Department of Neurology, Washington University School of Medicine, St. Louis, MO, c Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, Philadelphia, PA, d Banner Alzheimer's Institute, 901 East Willetta Street, Phoenix, AZ, e Center for Imaging of Neurodegenerative Diseases, Department of Radiology, San Francisco VA Medical Center/University of California San Francisco, San Francisco, CA. *These authors contributed equally to this paper. Acta Neuropathol. Commun. 2013;1:65

Participant Characteristics (n = 22) l Age = l Gender = 77% male l Education = y l APOE4+ = 50% l Clinically –1 CN to MCI –3 MCI stable –8 MCI to DAT –10 DAT l A clinical Dx of DAT or MCI due to AD was supported by a pathological Dx of AD in all cases l Other pathologies: TDP, SVD, DLB, AGD, HS

ADNI: Semi-quantitative Neuropathologic “Heat Map” Grading of ADNI Cases

DOD ADNI l The ADNI NP Core serves as the DOD ADNI NP Core –Cognitively normal when enrolled –No budget proposed “as few autopsies are expected during the period of the DOD grant” l DOD MCI ADNI grant also to be served by ADNI NP Core – through –2 brain autopsies estimated/budgeted per year

Proposed ADNI-3: Neuropathology Core Aims l Aim 1: Foster and facilitate voluntary brain autopsy for all deceased ADNI participants l Aim 2: Provide uniform neuropathological assessments on all autopsied ADNI participants l Aim 3: Maintain a repository of frozen and fixed brain tissue from ADNI participants l Aim 4: Conduct neuropathological correlative studies with biomarkers (CSF) and imaging measures of the molecular pathology (Aβ, tau) of Alzheimer disease